Free Trial
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel
NASDAQ:TNFA

TNF Pharmaceuticals 5/15/2025 Earnings Report

TNF Pharmaceuticals logo
$4.18 +0.10 (+2.45%)
As of 05/22/2026
ProfileEarnings HistoryForecast

TNF Pharmaceuticals EPS Results

Actual EPS
-$36.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

TNF Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TNF Pharmaceuticals Announcement Details

Quarter
Date
5/15/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

TNF Pharmaceuticals Earnings Headlines

TNF Pharmaceuticals (NASDAQ:TNFA) Trading Up 22.4% - Should You Buy?
May 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30781037
Why did QCLS stock surge over 60% today?
December 4, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/why-did-qcls-stock-surge-over-60-today/ar-AA1RJkpU
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel
 |  Porter & Company (Ad)
Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight
November 5, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/rheumatoid-arthritis-market-surge-2034-223100043.html
Forward Therapeutics Announces First Participants Dosed in Phase 1 Healthy Volunteer Study of FT2109, a Next-Generation TNF Signaling Inhibitor
October 30, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/forward-therapeutics-announces-first-participants-dosed-in-phase-1-healthy-volunteer-study-of-ft2109-a-next-generation-tnf-signaling-inhibitor-1035455199
Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"
September 26, 2025  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2025/09/25/10260815.htm
See More TNF Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TNF Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TNF Pharmaceuticals and other key companies, straight to your email.

About TNF Pharmaceuticals

TNF Pharmaceuticals (NASDAQ:TNFA) operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

View TNF Pharmaceuticals Profile
Earnings Tools